cyramza

cyramza Uses, Dosage, Side Effects, Food Interaction and all others data.

cyramza is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. cyramza is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.

Trade Name cyramza
Availability Prescription only
Generic Ramucirumab
Ramucirumab Other Names Ramucirumab
Related Drugs Opdivo, methotrexate, Keytruda, capecitabine, pembrolizumab, fluorouracil, doxorubicin, cisplatin, Tagrisso, Avastin
Weight 10mg/ml,
Type Injection, Solution, Infusion, Intravenous Solution
Formula C6374H9864N1692O1996S46
Weight 143600.0 Da
Groups Approved, Investigational
Therapeutic Class
Manufacturer Eli Lilly, Eli Lilly And Company Limited
Available Country Saudi Arabia, Australia, United Kingdom, United States,
Last Updated: September 19, 2023 at 7:00 am
cyramza
cyramza

Uses

cyramza is an antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.

For use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.

cyramza is also used to associated treatment for these conditions: Advanced Gastric Cancer, Advanced gastro-esophageal junction adenocarcinoma, Refractory, metastatic Colorectal cancer, Refractory, metastatic Non small cell lung cancer

How cyramza works

cyramza is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells.

Toxicity

cyramza packaging includes warnings for arterial thromboembolic events, hypertension, infusion-related reactions, gastrointestinal perforation, clinical deterioration in patients with cirrhosis, and reversible posterior leukoencephalopathy syndrome. The most common reactions observed in single-agent-treated patients at a rate of >10% and >2% higher than placebo were hypertension and diarrhea. The most common adverse reactions observed in patients treated with ramucirumab plus paclitaxel at a rate of of >30% and >2% higher than placebo plus paclitaxel were fatigue, neutropenia, diarrhea, and epistaxis.

Food Interaction

No interactions found.

Volume of Distribution

5.5 L

Half Life

15 days

Clearance

0.014 L/hour

Innovators Monograph

You find simplified version here cyramza

*** Taking medicines without doctor's advice can cause long-term problems.
Share